Brazil Health Regulator Approves Clinical Trials of Oxford COVID-19 Vaccine

The Oxford University vaccine, supported by AstraZeneca, is among the first COVID-19 vaccines to move into Phase II, or mid-stage, trials, along with one from the U.S. biotech company Moderna Inc.

RIO DE JANEIRO, BRAZIL - (Reuters) Brazil’s health regulator Anvisa has approved human clinical trials for a potential coronavirus vaccine developed by scientists at Oxford University and supported by AstraZeneca Plc, it said on Wednesday, June 3rd.

With COVID-19 epidemics in Britain, mainland Europe and the United States coming down from their peak and transmission rates of the coronavirus dropping, scientists have turned to places like Brazil, where the disease is still rife, to test potential . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?